Core Viewpoint - Junshi Biosciences (01877) experienced a significant stock increase of over 10%, attributed to the approval of clinical trial application for JT118, a dual-target recombinant protein vaccine aimed at preventing monkeypox virus infection [1] Group 1: Clinical Trial Approval - Junshi Biosciences' subsidiary, Shanghai Juntuo Biopharmaceutical Technology Co., Ltd., received the Drug Clinical Trial Approval Notification from the National Medical Products Administration for JT118 [1] - JT118 is a recombinant protein vaccine composed of monkeypox virus antigens A35 and M1, demonstrating significant protective effects in preclinical studies against both vaccinia virus and monkeypox virus in large animal models, with good safety profiles [1] Group 2: Research Recognition - Multiple research outcomes from Junshi Biosciences, including the anti-BTLA monoclonal antibody tifcemalimab and the anti-PD-1 monoclonal antibody treprilumab, have been selected for oral presentations and posters at the 2025 World Lung Cancer Conference (WCLC) scheduled for September 6-9, 2025, in Barcelona, Spain [1]

Core Viewpoint - Junshi Biosciences (688180.SH) announced that its subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of JT118 injection, aimed at preventing monkeypox virus infection [1] Group 1 - JT118 is a "dual-target" recombinant protein vaccine composed of monkeypox virus antigens A35 (extracellular membrane virus antigen) and M1 (intracellular mature virus antigen) [1] - The vaccine is primarily intended for the prevention of monkeypox virus infection, which is a zoonotic viral disease caused by the monkeypox virus [1] - The monkeypox virus is classified under the Poxviridae family and the Orthopoxvirus genus, producing two different infectious particle forms during replication: extracellular membrane virus and intracellular mature virus [1] Group 2 - JT118 retains the epitope structures of both natural antigens A35 and M1, while significantly increasing molecular weight through multi-antigen fusion, which is more conducive to immune activation [1]

Core Viewpoint - Junshi Bioscience's subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., has received acceptance for the clinical trial application of JT118 injection, a "dual-target" recombinant protein vaccine aimed at preventing monkeypox virus infection [1] Company Summary - Junshi Bioscience (688180.SH) announced that its subsidiary has received the acceptance notice from the National Medical Products Administration for the clinical trial application of JT118 injection [1] - JT118 is composed of monkeypox virus antigens A35 and M1, designed as a "two-in-one" recombinant protein vaccine [1] - As of the announcement date, there are no approved vaccines for preventing monkeypox virus infection in China [1] Industry Summary - The development cycle for pharmaceuticals is lengthy and involves multiple approval stages, leading to uncertainty regarding the approval of this clinical trial application [1]